secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACURA PHARMACEUTICALS, INC (—)
CIK:        0000786947
Form:       8-K
Filed at:   2026-06-29T20:16:08+00:00
Accession:  0001104659-26-078839
Event type: debt
Sentiment:  negative
Materiality: 0.95
Item codes: 1.01, 2.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acura extends loan maturity and NDA deadline with AD Pharma, warns of possible shutdown
--------------------------------------------------------------------------------

- Received $200,000 loan from AD Pharma on June 24, 2026, bringing principal balance to $10,694,279 with accrued interest of ~$1.16M.
- Extended NDA acceptance deadline for LTX-03 from June 30, 2026 to December 31, 2026 via amendment #14 to license agreement.
- Extended maturity date of secured promissory note from June 30, 2026 to December 31, 2026 via amendment #8.
- Extended warrant expiration date to December 31, 2026 and noted AD Pharma owns ~65% of outstanding common stock.
- Warns that without additional financing by late July 2026, may need to scale back operations, furlough employees, or seek bankruptcy protection.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/786947/000110465926078839/0001104659-26-078839-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/786947/000110465926078839/tm2619325d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-078839

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer